Delivery Order SPE2DB22D3501-SPE2DB25FUX74

Award Date 3/14/25
Potential Completion Date 3/17/25
Potential Value $1K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of ZORYVE 0.3% FOAM 60GM, a medical product, with a ceiling value of $1,476.28 and a final completion date of February 11, 2025. The award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026....
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,131.87, is a Delivery Order with a Firm Fixed Price pricing type. It is for the supply of "ZORYVE 0.3% FOAM 60GM" medical products, with an ultimate completion date of March 14, 2025. The award is not designated as a set-aside contract. Amerisourcebergen holds a significant Indefinite...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,831.73 firm-fixed-price delivery order is for the supply of ZORYVE 0.3% FOAM 60GM, with a performance period ending on December 9, 2024. The contract does not have a set-aside designation, indicating open competition. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,054.62 firm fixed-price delivery order is for the pharmaceutical product ZORYVE 0.3% Cream, 60 GM. The contract has a period of performance through February 6, 2025 and was awarded on February 5, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award, with an ID of SPE2DB22D1106|SPE2DB25FDSR8, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,897.25 firm fixed price delivery order contract is for the supply of ZORYVE 0.3% FOAM 60GM, a medical product. The award is associated with a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at...
The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract to AmerisourceBergen Drug Corp in the amount of $12,485.88 for the supply of ZORYVE 0.3% FOAM 60GM. This contract has a period of performance through September 10, 2024 and is not set aside for any special designation. AmerisourceBergen, a major pharmaceutical distributor, is providing these prescription dermatological products through an existing Indefinite Delivery Contract (IDC) with DLA Troop Support...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,781.33 firm fixed-price delivery order is for the supply of 4567585489 ! ZORYVE 0.3% FOAM 60GM medical products, with a period of performance through March 17, 2025. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, for the supply of the prescription drug ZORYVE 0.3% Cream 60GM. The contract has a firm fixed price of $2,423.28 and a completion date of November 6, 2024. This award is not associated with any set-aside designation, indicating open competition. The contract is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,455.43 firm fixed-price delivery order is for ZORYVE 0.3% Cream, a pharmaceutical product, with a period of performance through January 24, 2025. The contract is not designated as a set-aside. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award, with ID SPE2DB22D3301|SPE2DB25FX5JN, was granted by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of ZORYVE 0.3% CREAM 60GM, a medical product, with a ceiling value of $6,712.54 and a completion date of November 13, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
  • SPE2DB22D3501
    Indefinite Delivery Contract
  • SPE2DB22D3501-SPE2DB25FUX74
    Delivery Order

This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Zoryve 0.3% foam, a pharmaceutical product. The contract has a firm fixed price of $1,017.75 and a completion date of March 17, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.

Generated 6/13/25, 9:46 AM